W
WAVEMAN · COMPANY
VBIO · Valion Bio, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

VBIO

Valion Bio, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001787740
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-33.7%
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
2
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-33.7% year over year
below 78% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3i, LP disclosed a 5%+ stake (9.9%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -9.2%
-9.2%12M
-91%-9%+72%+154%2025-092025-102025-122026-032026-052026-072026-09 2026-08-03 · 3i, LP filed a 5%+ stake (9.9%)2026-08-03 · Tumim Stone Capital, LLC filed a 5%+ stake (1.1%)2026-08-03 · 3i Management LLC filed a 5%+ stake (9.9%)2026-08-03 · Maier J. Tarlow filed a 5%+ stake (9.9%)
13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
Every figure on this page is a federal filing, dated the day it became public — so you can test what was knowable, not what is known now.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Valion Bio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
LoConti Joseph E.
—
BUY
2021-07-29
1,000.0
$200
LoConti Joseph E.
—
BUY
2021-07-20
13,000.0
$2.6K
LoConti Joseph E.
—
BUY
2021-07-19
20,000.0
$4.0K
LoConti Joseph E.
—
BUY
2021-07-19
67,000.0
$12.7K
LoConti Joseph E.
—
BUY
2021-07-19
40,000.0
$6.4K
14 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 9 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

5%+ owners
13D = intent to influence · 13G = passive
3i, LP
ACTIVIST 13D · 2026-08-03
9.9%
Tumim Stone Capital, LLC
ACTIVIST 13D · 2026-08-03
1.1%
3i Management LLC
ACTIVIST 13D · 2026-08-03
9.9%
Maier J. Tarlow
ACTIVIST 13D · 2026-08-03
9.9%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE—$780.0K$1.2M$1.8M
GROSS PROFIT—$2.0K$287.0K$299.0K
OPERATING INCOME$-7.9M$-4.5M$-8.2M$-10.1M
NET INCOME$-8.9M$-5.7M$-8.2M$-10.1M
EPS (DILUTED)—-19.68-176.80-104.32
OPERATING CASH FLOW$-7.0M$-5.7M$-8.5M$-8.9M
CASH$12.6M$2.0M$3.4M$3.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →